China-based nucleic acid drug developer Suzhou Abogen Biosciences and Ruijin Hospital, a comprehensive Class 3A hospital in Shanghai, have jointly announced the establishment of the Ruijin Abogen Nucleic Acid Drug Research Institute. The new institute aims to further explore the application of mRNA drugs in tumors and autoimmune diseases, with a focus on boosting innovation and clinical translation in these areas.
Collaboration on mRNA Drug Development
The partnership between Suzhou Abogen Biosciences and Ruijin Hospital began in June 2024, and since then, multiple programs have entered into investigator-initiated trials (IITs). These trials cover a range of cancer types, including lung cancer, pancreatic cancer, and colorectal cancer. The collaboration signifies a significant step forward in advancing mRNA-based therapeutics for oncological applications.
Accelerating Clinical Translation of mRNA Therapies
The establishment of the Ruijin Abogen Nucleic Acid Drug Research Institute underscores the commitment of both Suzhou Abogen Biosciences and Ruijin Hospital to drive forward mRNA drug research. By combining their expertise and resources, the institute is poised to accelerate the development and clinical translation of mRNA drugs, potentially offering new treatment options for patients suffering from various cancers and autoimmune diseases.-Fineline Info & Tech
